Zentalis FY2025 operating loss narrows 20.1% to $152.8 million; loss per share narrows to $1.91

Reuters03-27

Zentalis FY2025 operating loss narrows 20.1% to $152.8 million; loss per share narrows to $1.91

Zentalis published a press release reporting full-year 2025 financial results and operational updates.
Net loss attributable to shareholders was USD 137.1 million, or USD 1.91 per share (basic and diluted).
Research and development expenses fell 36.07% to USD 107.3 million, driven mainly by lower clinical expenses, lab services, drug manufacturing, and personnel costs.
General and administrative expenses dropped 56.71% to USD 37.7 million, primarily due to lower personnel expense including reduced non-cash stock-based compensation.
Cash, cash equivalents and marketable securities were USD 245.9 million as of Dec. 31, 2025, and Zentalis said this is expected to fund operations into late 2027 as it targets DENALI Part 2a dose confirmation and ASPENOVA Phase 3 initiation in 1H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622962918?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622962918","market":"us","top_or_hot":-1,"title":"Zentalis FY2025 operating loss narrows 20.1% to $152.8 million; loss per share narrows to $1.91","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zentalis FY2025 operating loss narrows 20.1% to $152.8 million; loss per share narrows to $1.91\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Zentalis published a press release reporting full-year 2025 financial results and operational updates.\n        </li>\n<li>\n          Net loss attributable to shareholders was USD 137.1 million, or USD 1.91 per share (basic and diluted).\n        </li>\n<li>\n          Research and development expenses fell 36.07% to USD 107.3 million, driven mainly by lower clinical expenses, lab services, drug manufacturing, and personnel costs.\n        </li>\n<li>\n          General and administrative expenses dropped 56.71% to USD 37.7 million, primarily due to lower personnel expense including reduced non-cash stock-based compensation.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities were USD 245.9 million as of Dec. 31, 2025, and Zentalis said this is expected to fund operations into late 2027 as it targets DENALI Part 2a dose confirmation and ASPENOVA Phase 3 initiation in 1H 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zentalis FY2025 operating loss narrows 20.1% to $152.8 million; loss per share narrows to $1.91</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZentalis FY2025 operating loss narrows 20.1% to $152.8 million; loss per share narrows to $1.91\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 04:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zentalis FY2025 operating loss narrows 20.1% to $152.8 million; loss per share narrows to $1.91\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Zentalis published a press release reporting full-year 2025 financial results and operational updates.\n        </li>\n<li>\n          Net loss attributable to shareholders was USD 137.1 million, or USD 1.91 per share (basic and diluted).\n        </li>\n<li>\n          Research and development expenses fell 36.07% to USD 107.3 million, driven mainly by lower clinical expenses, lab services, drug manufacturing, and personnel costs.\n        </li>\n<li>\n          General and administrative expenses dropped 56.71% to USD 37.7 million, primarily due to lower personnel expense including reduced non-cash stock-based compensation.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities were USD 245.9 million as of Dec. 31, 2025, and Zentalis said this is expected to fund operations into late 2027 as it targets DENALI Part 2a dose confirmation and ASPENOVA Phase 3 initiation in 1H 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZNTL","symbol_name":"Zentalis Pharmaceuticals, LLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL830xlM:1","article_id":"2622962918","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622962918","pubTimestamp":1774555875,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zentalis published a press release reporting full-year 2025 financial results and operational updates.Net loss attributable to shareholders was USD 137.1 million, or USD 1.91 per share .Research and development expenses fell 36.07% to USD 107.3 million, driven mainly by lower clinical expenses, lab services, drug manufacturing, and personnel costs.General and administrative expenses dropped 56.71% to USD 37.7 million, primarily due to lower personnel expense including reduced non-cash stock-based compensation.Cash, cash equivalents and marketable securities were USD 245.9 million as of Dec. 31, 2025, and Zentalis said this is expected to fund operations into late 2027 as it targets DENALI Part 2a dose confirmation and ASPENOVA Phase 3 initiation in 1H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZNTL":"Zentalis Pharmaceuticals, LLC","BK4139":"生物科技"},"translate_title":"Zentalis 2025财年运营亏损收窄20.1%至1.528亿美元；每股亏损收窄至1.91美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZNTL":0.9},"content_text":"Zentalis FY2025 operating loss narrows 20.1% to $152.8 million; loss per share narrows to $1.91\n    \n\n\n          Zentalis published a press release reporting full-year 2025 financial results and operational updates.\n        \n\n          Net loss attributable to shareholders was USD 137.1 million, or USD 1.91 per share (basic and diluted).\n        \n\n          Research and development expenses fell 36.07% to USD 107.3 million, driven mainly by lower clinical expenses, lab services, drug manufacturing, and personnel costs.\n        \n\n          General and administrative expenses dropped 56.71% to USD 37.7 million, primarily due to lower personnel expense including reduced non-cash stock-based compensation.\n        \n\n          Cash, cash equivalents and marketable securities were USD 245.9 million as of Dec. 31, 2025, and Zentalis said this is expected to fund operations into late 2027 as it targets DENALI Part 2a dose confirmation and ASPENOVA Phase 3 initiation in 1H 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622962918","isCrawlerRequest":true}